terça-feira, 27 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 8, 2026

Leidos downgraded by J.P. Morgan as defense stocks face rocky earnings season

View original at seekingalpha.com
Leidos downgraded by J.P. Morgan as defense stocks face rocky earnings season [two soldiers in action] StudioThreeDots/iStock via Getty Images J.P…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Leidos downgraded to Neutral from Overweight on deteriorating earnings expectations.

    60% confidence
  • J.P. Morgan remains more cautious on Northrop Grumman because of its limited missile demand exposure and the F/A-XX loss.

    60% confidence
  • Lockheed Martin and Huntington Ingalls are preferred defense stocks heading into Q3 results, though both are rated Neutral.

    60% confidence
  • Leidos' relatively low valuation is insufficient to justify an Overweight rating when other aerospace and defense stocks also offer substantial potential returns.

    60% confidence
  • Most aerospace and defense companies should deliver solid Q3 results and express confidence in underlying demand, but good earnings may not reverse the sector's stock-market weakness.

    60% confidence
  • Price target on Leidos lowered to $142 from $160, reflecting concerns about the Health business and potential further earnings disappointments.

    60% confidence
  • J.P. Morgan forecasts Boeing revenue of $108.46 billion in 2027 versus $96.31 billion in 2026, and adjusted free cash flow of about $5.55 billion versus $1.84 billion.

    60% confidence
  • StandardAero maintained at Overweight with a $40 price target, citing opportunities in commercial engine maintenance and higher-margin component repair.

    60% confidence
  • TransDigm could benefit from a stronger-than-expected initial fiscal 2027 outlook, and aftermarket demand should remain healthy.

    60% confidence
  • Howmet, Honeywell Aerospace, Huntington Ingalls and Lockheed Martin are potential outperformers during Q3 earnings season.

    60% confidence
  • Howmet's 2026 earnings estimates are expected to increase, and management is expected to remain confident about growth in aerospace and industrial gas turbines.

    60% confidence
  • A&D stocks were weak in Q3 and sentiment is sour, even though the broader market is near an all-time high.

    60% confidence
  • Bloomberg consensus still anticipates about $2.45 billion in Leidos adjusted EBITDA for 2027, suggesting published expectations may be too optimistic.

    60% confidence
  • Expectations for Honeywell Aerospace have fallen enough to limit additional downside, provided the company avoids an earnings miss.

    60% confidence
  • Boeing maintained at Overweight with a $290 price target; the bank sees potential for improved 737 and 787 production, advancement of the 777X and stabilization of the defense business.

    60% confidence
  • Huntington Ingalls could benefit from progress on CVN-79 milestones and a July submarine contract, supporting profitability and cash flow expectations through the rest of 2026.

    60% confidence
  • The preferred approach is to focus on companies with opportunities for upward earnings revisions or sufficiently depressed expectations to support a rebound.

    60% confidence
  • Expectations for Boeing's 2027 cash flow have weakened, and uncertainty about aircraft production rates has contributed to investor caution.

    60% confidence
  • Leidos' adjusted EBITDA margin is expected to decline to 11.8% from 13.3%, largely because Health segment margins are projected to fall to 16% from 22%.

    60% confidence
  • Stagnant global air traffic could eventually reduce maintenance demand, but an engine maintenance backlog should support aerospace aftermarket suppliers for several more quarters.

    60% confidence
  • J.P. Morgan forecasts Leidos' 2027 revenue at about $18.1 billion versus $18.35 billion in 2026, and adjusted EBITDA falling to $2.14 billion from $2.45 billion.

    60% confidence
  • J.P. Morgan expects continued execution improvements and significant backlog growth from missile contracts at Lockheed Martin.

    60% confidence
  • Election-related uncertainty may dissipate after Nov. 3, but fiscal 2027 federal budget negotiations may continue well beyond Election Day. Rising government borrowing costs are a longer-term concern for discretionary defense spending.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,994
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,994 factos verificados com a fonte5,500 documentos-fonte arquivados
Consulte estes dados → isubstrate.com